WuXi AppTec
Search results
Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.
WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.
One of the world’s largest facilities utilising single-use bioreactor technology featuring 2 drug substance manufacturing suites: 48,000L Fed-batch (MFG6) and 6,000L perfusion (MFG7) Construction began in 2019, and operations commenced in 2021, creating 800 jobs.
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations...
微生物. 大肠杆菌及酵母表达系统，一体化CMC开发及cGMP生产微生物发酵平台. 质量. 通过FDA, EMA 和 NMPA认证的一流质量体系. 病毒. 全球化一站式CMC开发,多个在建或已投产的cGMP基地用于生产病毒产品及疫苗. 全球布局. 预计到2026年后，公司在中国、爱尔兰、美国、德国和新加坡规划的生物制药生产基地合计产能将超过58万升。 美国. 爱尔兰. 德国. 新加坡. 中国. 卓越的质量标准. 我们提供符合或超越全球法规标准的质量保证、质量控制与运营体系。 药明生物卓越的质量体系已被多个全球监管机构认证，为多种生物制剂和疫苗的生产护航。 了解详情. 时间截至2024年6月. 15. 个. GMP认证的厂房. 37. 次.
WuXi Biology provides a full spectrum of services and solutions to support stand-alone and integrated projects, from target discovery to candidate selection and into the clinic. Our world-class discovery platform is backed by nearly 3000 scientists, offering expertise in all major disease areas and target classes, across all therapeutic modalities.
Mar 19, 2024 · WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has broken ground on its new 13.5-hectare CRDMO center in Tuas Biomedical Park, Singapore.
Quality. Expertise. Capacity. Speed. These are cornerstones of every service WuXi Biologics provides across the discovery to commercialization spectrum.
Find the latest WuXi Biologics (Cayman) Inc. (2269.HK) stock quote, history, news and other vital information to help you with your stock trading and investing.
